EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische Studie

Atezolizumab Combined With Platinum and Maintenance Niraparib for Recurrent Ovarian Cancer With a Platinum-Free Interval >6 Months: ENGOT-OV41/GEICO 69-O/ANITA Phase III Trial

Antonio González-Martín iD, María Jesús Rubio iD, Florian Heitz iD, René Depont Christensen, Nicoletta Colombo iD, Toon Van Gorp iD, Margarita Romeo iD, Isabelle Ray-Coquard iD, Lydia Gaba iD, Alexandra Leary iD, Luis Miguel De Sande, Coriolan Lebreton iD und 24 weitere

Journal of Clinical Oncology · 2024

DOI: 10.1200/jco.24.00668 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, 2024. Verfasst von Antonio González-Martín und 35 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology Department, Translational Oncology Group, CIMA, Universidad de Navarra, Cancer Center Clínica Universidad de Navarra, Madrid, Spain. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Piperidines, Ovarian Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 21 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE To evaluate atezolizumab combined with platinum-based chemotherapy (CT) followed by maintenance niraparib for late-relapsing recurrent ovarian cancer. METHODS The multicenter placebo-controlled double-blind randomized phase III ENGOT-OV41/GEICO 69-O/ANITA trial (ClinicalTrials.gov identifier: NCT03598270 ) enrolled patients with measurable high-grade serous, endometrioid, or undifferentiated recurrent ovarian cancer who had received one or two previous CT lines (most recent including platinum) and had a treatment-free interval since last platinum (TFIp) of >6 months. Patients were stratified by investigator-selected carboplatin doublet, TFIp, BRCA status, and PD-L1 status in de novo biopsy and randomly assigned 1:1 to receive either atezolizumab or placebo throughout standard therapy comprising six cycles of a carboplatin doublet followed (in patients with response/stable disease) by maintenance niraparib until progression. The primary end point was investigator-assessed progression-free survival (PFS) per RECIST v1.1. RESULTS Between November 2018 and January 2022, 417 patients were randomly assigned (15% BRCA- mutated, 36% PD-L1–positive, 66% TFIp >12 months, 11% previous poly [ADP-ribose] polymerase inhibitor after frontline CT, and 53% previous bevacizumab). Median follow-up was 28.6 months (95% CI, 26.6 to 30.5 months). Atezolizumab did not significantly improve PFS (hazard ratio, 0.89 [95% CI, 0.71 to 1.10]; P = .28). Median PFS was 11.2 months (95% CI, 10.1 to 12.1 months) with atezolizumab versus 10.1 months (95% CI, 9.2 to 11.2 months) with standard therapy. Subgroup analyses generally showed consistent results, including analyses by PD-L1 status. The objective response rate (ORR) was 45% (95% CI, 39 to 52) with atezolizumab and 43% (95% CI, 36 to 49) with standard therapy. The safety profile was as expected from previous experience of these drugs. CONCLUSION Combining atezolizumab with CT and maintenance niraparib for late-relapsing recurrent ovarian cancer did not significantly improve PFS or the ORR.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedPiperidinesOvarian NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsIndazolesNeoplasm Recurrence, LocalCarboplatinHumansFemaleMiddle AgedAgedDouble-Blind MethodPhthalazinesAdultMaintenance ChemotherapyProgression-Free Survival

Substanzen

niraparibatezolizumabAntibodies, Monoclonal, HumanizedPiperidinesIndazolesCarboplatinPhthalazines

Autor:innen und Institutionen

  • Medical Oncology Department, Translational Oncology Group, CIMA, Universidad de Navarra, Cancer Center Clínica Universidad de Navarra, Madrid, Spain.
  • Grupo Español de Investigación en Cáncer ginecológicO (GEICO), Madrid, Spain.
  • Medical Oncology Department, Reina Sofia University Hospital of Cordoba, Cordoba, Spain.
  • Department for Gynaecology and Gynaecologic Oncology, Kliniken Essen-Mitte, Essen, Germany.
  • Department of Gynaecology, Berlin Institute of Health, Charité-Universitätsmedizin Berlin, Humboldt-Universität zu Berlin, Berlin, Germany.
  • Arbeitsgemeinschaft Gynaekologische Onkologie (AGO), Wiesbaden, Germany.

ORCID-Profile: Antonio González-Martín, María Jesús Rubio, Florian Heitz, Nicoletta Colombo, Toon Van Gorp, Margarita Romeo, Isabelle Ray-Coquard, Lydia Gaba, Alexandra Leary, Coriolan Lebreton, Maria-Pilar Barretina Ginesta, J Alejandro Pérez-Fidalgo, Manuel Rodrigues, Renaud Sabatier, Gloria Marquina, Luisa Sánchez-Lorenzo, Purificación Estévez-García, Luis Manso, Germana Tognon, Stéphanie Henry, Ana Oaknin

Zitieren

APA

González-Martín, A., Rubio, M. J., Heitz, F., Depont Christensen, R., Colombo, N., Van Gorp, T., Romeo, M., Ray-Coquard, I., Gaba, L., Leary, A., De Sande, L. M., Lebreton, C., Redondo, A., Fabbro, M., Barretina Ginesta, M. P., Follana, P., Pérez-Fidalgo, J. A., Rodrigues, M., Santaballa, A., …, & Selle, F. (2024). Atezolizumab Combined With Platinum and Maintenance Niraparib for Recurrent Ovarian Cancer With a Platinum-Free Interval >6 Months: ENGOT-OV41/GEICO 69-O/ANITA Phase III Trial. Journal of Clinical Oncology. https://doi.org/10.1200/jco.24.00668

Vancouver

González-Martín A, Rubio MJ, Heitz F, Depont Christensen R, Colombo N, Van Gorp T, et al. Atezolizumab Combined With Platinum and Maintenance Niraparib for Recurrent Ovarian Cancer With a Platinum-Free Interval >6 Months: ENGOT-OV41/GEICO 69-O/ANITA Phase III Trial. Journal of Clinical Oncology. 2024. doi:10.1200/jco.24.00668

BibTeX
@article{GonzlezMartn2024,
  author = {González-Martín, Antonio and Rubio, María Jesús and Heitz, Florian and Depont Christensen, René and Colombo, Nicoletta and Van Gorp, Toon and Romeo, Margarita and Ray-Coquard, Isabelle and Gaba, Lydia and Leary, Alexandra and De Sande, Luis Miguel and Lebreton, Coriolan and Redondo, Andrés and Fabbro, Michel and Barretina Ginesta, Maria-Pilar and Follana, Philippe and Pérez-Fidalgo, J Alejandro and Rodrigues, Manuel and Santaballa, Ana and Sabatier, Renaud and Bermejo-Pérez, Maria José and Lotz, Jean-Pierre and Pardo, Beatriz and Marquina, Gloria and Sánchez-Lorenzo, Luisa and Quindós, María and Estévez-García, Purificación and Guerra Alía, Eva and Manso, Luis and Casado, Victoria and Kommoss, Stefan and Tognon, Germana and Henry, Stéphanie and Bruchim, Ilan and Oaknin, Ana and Selle, Frédéric},
  title = {Atezolizumab Combined With Platinum and Maintenance Niraparib for Recurrent Ovarian Cancer With a Platinum-Free Interval >6 Months: ENGOT-OV41/GEICO 69-O/ANITA Phase III Trial},
  journal = {Journal of Clinical Oncology},
  year = {2024},
  doi = {10.1200/jco.24.00668}
}
Kostenlos starten →